BillionToOne Q3 net income more than triples to $17.39 million
BLLN•BillionToOne’s third-quarter 2026 net income more than tripled to $17.39 million. Revenue rose 47% to $123 million, and the company raised its 2026 revenue guidance to $460 million–$470 million.
1. Quarterly results
BillionToOne’s third-quarter 2026 diluted earnings per share more than tripled year over year to $0.32. Revenue increased 47% to $123 million, driven by higher test volume and average selling prices.
2. Outlook and product launch
The company raised its full-year 2026 revenue guidance to $460 million–$470 million and expects profitability to remain near current levels despite continued investment. Northstar Clear, a blood-only MRD test for patients with all solid tumors, is scheduled to launch commercially on December 15, 2026.
